- Life Sciences
- Conference
World CB & CDx Summit 2026
Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to attend the World CB & CDx Summit Boston 2026 and present how Tempus can support your global clinical development programs.
The new frontier of precision medicine - from tumor fingerprint to dose: Integrating data and NGS to power neoantigen therapies
The paradigm of precision oncology is shifting from standard biomarker targeting to highly personalized, data-driven therapies. In this fireside chat, Kate Sasser, Chief Scientific Officer of Tempus, and Said Francis, Chief Business Officer and General Manager of Individualized Neoantigen Therapies at Moderna, discuss how combining next-generation sequencing (NGS) and advanced therapeutic platforms is accelerating the development of neoantigen therapies and personalized medicines, and has the potential to transform cancer care.
Kate Sasser, PhD, Chief Scientific Officer, Tempus
Said Francis, Chief Business Officer & General Manager, Individualized Neoantigen Therapy (INT), Moderna
Schedule a meeting with us
We'll be in touch shortly.